Pre-IND meeting has been scheduled with FDA to advance type 1 diabetes treatment to First-In-Human clinical trial ZURICH, Switzerland, May 27, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (("NewcelX", NASDAQ:NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, today announced the submission of a Pre-Investigational New Drug ("Pre-IND") briefing package to the U.S. Food and Drug Administration ("FDA") to support the proposed First-In-Human ("FIH") clinical trial of NCEL-101 in combination with tegoprubart, an investigational immunomodulatory agent being developed by Eledon Pharmaceuticals (("Eledon", NASDAQ:ELDN). The submission represents a significant mi

NewcelX and Eledon Pharmaceuticals are collaborating to advance one of the few scalable approaches to a potential functional cure in Type 1 Diabetes, NCEL-101, as the flagship program and key long-term value driver toward IND-enabling milestones Substantially debt free, NewcelX recently closed a financing of up to approximately $3.4 million, including $1.35 million in cash and approximately $2 million of potential additional proceeds from the exercise of warrants, and has access to up to a $25 million Equity Line of Credit Strengthened scientific leadership with appointment of Julien Boisdron, MD, Chief Medical Officer of a Swiss Big Pharma, to Scientific Advisory Board Aims to significan

ZURICH, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (NASDAQ:NCEL),– NewcelX Ltd. (NASDAQ:NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, today announced the release of an updated corporate presentation that includes the company's strategic collaboration with Eledon Pharmaceuticals (NASDAQ:ELDN) and highlights the advancement of its flagship Type 1 Diabetes program, NCEL-101, as a central pillar of the company's development strategy. The updated presentation outlines the integration of NewcelX's scalable stem-cell-derived islet replacement platform with Eledon's investigational anti-CD40L monoclonal antibody tegoprubart, a targ

Financing reflects strong investor confidence and supports advancement of lead Type 1 Diabetes program ZURICH, Switzerland, April 01, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (NASDAQ:NCEL), a clinical-stage biopharmaceutical company developing stem cell-based therapies for Type 1 Diabetes, today announced that it has entered into securities purchase agreements for a private placement at a purchase price of $2.75 per share, representing a 30% premium to the last closing price of the Company's common shares on March 31, 2026. Pursuant to the terms of the securities purchase agreements, the Company is selling an aggregate of 490,907 common shares (and common share equivalents) and one series o

Collaboration Integrates Stem-Cell-Derived Islets with Targeted Immune ModulationZURICH, Switzerland, March 9, 2026 /PRNewswire/ -- NewcelX Ltd. ("NewcelX") (NASDAQ:NCEL), a clinical-stage company advancing stem-cell-derived therapies for Type 1 Diabetes, today announced a collaborative research agreement with Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN), a clinical-stage immunology company with a focus on transplant medicine. The collaboration is designed to advance combination strategies integrating NewcelX's lead program, NCEL-101, with Eledon's investigational anti-

Publication strengthens scientific positioning as Company progresses strategic discussions related to CVR-linked asset ZURICH, Feb. 12, 2026 /PRNewswire/ -- NewcelX Ltd. ("NewcelX" or the "Company") (NASDAQ:NCEL), a clinical-stage biopharmaceutical company advancing stem-cell-derived therapies for Type 1 Diabetes and advancing innovative therapies for central nervous system (CNS) today announced the publication of a comprehensive peer-reviewed scientific review entitled, "Mazindol Immediate-Release/Sustained-Release (IR/SR): A 50-Year Legacy of Multifaceted Mechanisms and Emerging Therapeutic Potential," in Clinical Drug Investigation, a Springer Nature journal. The article is available at:

Reinforces strategic focus on Type 1 Diabetes cell therapy and highlights expansion of Scientific Advisory Board and leadership team ZURICH, Jan. 29, 2026 /PRNewswire/ -- NewcelX Ltd. (NASDAQ:NCEL) ("NewcelX" or the "Company"), a clinical-stage cell therapy company advancing transformative treatments for chronic metabolic and neurodegenerative diseases, today announced the release of an updated corporate presentation in advance of its participation in several major spring 2026 investor and partnering conferences, including BIO-Europe Spring in Lisbon. The updated corporate deck reflects NewcelX's sharpened strategic focus on its lead cell therapy programs for Type 1 Diabetes, highlighting r

ZURICH, Jan. 12, 2026 /PRNewswire/ -- NewcelX Ltd. (NASDAQ:NCEL) ("NewcelX" or the "Company"), a clinical-stage biotechnology company advancing regenerative medicine solutions, today reported the results of an international collaborative research study investigating advanced biomaterial strategies to support the delivery and function of stem cell–derived islets for the treatment of Type 1 Diabetes. The peer reviewed study, published in Diabetology, a journal dedicated to diabetes research, conducted in collaboration with research groups from the University of Technology Sydney, the University of Wisconsin–Madison, Monash University, the Queensland University of Technology, and the Australia

ZURICH and NESS ZIONA, Israel, Jan. 5, 2026 /PRNewswire/ -- NewcelX Ltd. (NASDAQ:NCEL) ("NewcelX"), a biotechnology company developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases, today announced the appointment of Dr. Julien Boisdron, MD, a seasoned diabetes expert with extensive experience in Swiss big pharma leadership to its Scientific Advisory Board ("SAB"). Dr. Boisdron brings more than two decades of global leadership in diabetes care. He currently serves as Chief Medical Officer for a major Swiss-based multinational large cap ph

Publication in key market advances NewcelX's global IP strategy across Asia and supports the Company's expanding position in neurology and metabolic diseases ZURICH, Dec. 11, 2025 /PRNewswire/ -- NewcelX Ltd. (NASDAQ:NCEL), a next-generation biotechnology company developing advanced cell-therapy and neuroscience-driven therapeutics, today announced the publication of a major international patent application in China covering a new class of quinazoline, benzothiazine, and benzoxazine derivatives (DOXA) for the treatment of neurological diseases. This publication marks an import

6-K - NewcelX Ltd. (0001783036) (Filer)

EFFECT - NewcelX Ltd. (0001783036) (Filer)

D - NewcelX Ltd. (0001783036) (Filer)

F-3 - NewcelX Ltd. (0001783036) (Filer)

EFFECT - NewcelX Ltd. (0001783036) (Filer)

POS AM - NewcelX Ltd. (0001783036) (Filer)

6-K - NewcelX Ltd. (0001783036) (Filer)

20-F - NewcelX Ltd. (0001783036) (Filer)

6-K - NewcelX Ltd. (0001783036) (Filer)

6-K - NewcelX Ltd. (0001783036) (Filer)

4 - NewcelX Ltd. (0001783036) (Issuer)

4 - NewcelX Ltd. (0001783036) (Issuer)

3 - NewcelX Ltd. (0001783036) (Issuer)

3 - NewcelX Ltd. (0001783036) (Issuer)

3 - NewcelX Ltd. (0001783036) (Issuer)

3 - NewcelX Ltd. (0001783036) (Issuer)

3 - NewcelX Ltd. (0001783036) (Issuer)

3 - NewcelX Ltd. (0001783036) (Issuer)

3 - NewcelX Ltd. (0001783036) (Issuer)

3 - NewcelX Ltd. (0001783036) (Issuer)

4 - NewcelX Ltd. (0001783036) (Issuer)

4 - NewcelX Ltd. (0001783036) (Issuer)

ZURICH and NESS ZIONA, Israel, Jan. 5, 2026 /PRNewswire/ -- NewcelX Ltd. (NASDAQ:NCEL) ("NewcelX"), a biotechnology company developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases, today announced the appointment of Dr. Julien Boisdron, MD, a seasoned diabetes expert with extensive experience in Swiss big pharma leadership to its Scientific Advisory Board ("SAB"). Dr. Boisdron brings more than two decades of global leadership in diabetes care. He currently serves as Chief Medical Officer for a major Swiss-based multinational large cap ph

ZURICH and NESS ZIONA, Israel, Nov. 17, 2025 /PRNewswire/ -- NewcelX Ltd. (NASDAQ:NCEL) ("NewcelX" or "the Company"), a clinical-stage biotechnology company developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases, today announced the appointment of Prof. Jeremy Shefner, MD, PhD, to the Company's Scientific Advisory Board ("SAB").   Prof. Shefner is a highly respected neurologist specializing in amyotrophic lateral sclerosis (ALS) and neuromuscular disorders. He serves as Professor of Neurology and Chief Medical Officer for Clinical Research at Barrow Neurological Institute in Phoenix, Arizona — an internationally recognized leader in the treatment and

NewcelX and Eledon Pharmaceuticals are collaborating to advance one of the few scalable approaches to a potential functional cure in Type 1 Diabetes, NCEL-101, as the flagship program and key long-term value driver toward IND-enabling milestones Substantially debt free, NewcelX recently closed a financing of up to approximately $3.4 million, including $1.35 million in cash and approximately $2 million of potential additional proceeds from the exercise of warrants, and has access to up to a $25 million Equity Line of Credit Strengthened scientific leadership with appointment of Julien Boisdron, MD, Chief Medical Officer of a Swiss Big Pharma, to Scientific Advisory Board Aims to significan